Global Pharmacy Market Size and Revenue
The global pharmacy market generated an estimated 1.3 trillion dollars in total drug sales in 2024, with retail pharmacy chains accounting for the largest share of revenue. The top 10 pharmacy chains in the United States alone processed over 5 billion prescriptions combined, according to industry reports and public filings Forbes top pharmacy chains data. Major chains such as CVS Health, Walgreens Boots Alliance, and Walmart continue to dominate the U.S. market, with CVS Health reporting total revenues above 350 billion dollars for the fiscal year ending in early 2024.
Pharmacy benefit managers (PBMs) such as Express Scripts, CVS Caremark, and OptumRx control a significant portion of prescription drug spending by managing formularies and negotiating rebates with manufacturers. In 2024, the three largest PBMs administered prescriptions for over 300 million Americans, according to public company disclosures and regulatory filings SEC Express Scripts 10-K filings. These entities influence which medications are covered and at what cost, making them central players in the pharmacy supply chain.
Drug Pricing Trends and Cost Drivers
Average wholesale acquisition costs for brand-name prescription drugs rose by roughly 6 percent in 2024, continuing a trend of double-digit annual list price increases over the past decade. Specialty drugs, particularly those treating cancer, autoimmune conditions, and rare diseases, now account for more than half of total U.S. prescription drug spending despite representing a small fraction of prescriptions Forbes specialty drug spending data. Insulin prices, a frequent policy focus, declined modestly in early 2024 following federal negotiation efforts and manufacturer commitments, though many patients still pay over 300 dollars per month out of pocket.
Key Factors Behind Rising Drug Costs
High research and development costs, patent protections, and limited generic competition remain primary drivers of expensive medications. The FDA approved fewer than 50 new generic drugs in 2024, slowing the entry of lower-cost alternatives for several widely used treatments FDA generic drug approvals page. Additionally, pharmacy benefit manager rebate structures and opaque pricing practices continue to draw scrutiny from regulators and lawmakers.
Regulation, Safety, and Emerging Pharmacy Models
The U.S. Food and Drug Administration oversees drug approval, manufacturing standards, and post-market safety monitoring, with the Center for Drug Evaluation and Research reviewing thousands of applications annually. In 2024, the FDA granted full approval to several new biosimilars and expanded indications for existing therapies, increasing treatment options while putting downward pressure on prices through competition FDA therapeutic biological products page. State boards of pharmacy regulate licensing, dispensing practices, and pharmacist scope of practice, with telepharmacy and mail-order services expanding rapidly after the pandemic.
Online and Automated Pharmacy Growth
Major technology and healthcare companies have invested in pharmacy automation, AI-driven dispensing systems, and direct-to-consumer prescription platforms. Amazon Pharmacy, which launched full nationwide operations in 2023, now serves millions of customers with home delivery and discounted pricing for Prime members